StocksMedium•5 November 2026•
1 min read
Iovance Biotherapeutics Reports Record $122 Million Q3 Revenue
Key Facts
1Iovance reported record Q3 2026 revenue of approximately $122 million, representing an 80% year-over-year increase.
2U.S. Amtagvi revenue increased 77% year-over-year, with gross margins improving to approximately 60%.
3The company reported a 24.6% objective response rate (ORR) in patients with non-squamous metastatic non-small-cell lung cancer.
Iovance Biotherapeutics reported record Q3 2026 revenue of approximately $122 million, marking an 80% increase compared to the previous year. GlobeNewswire reported that U.S. revenue for the drug Amtagvi rose by 77% year-over-year, helping the company's gross margin improve to approximately 60%.
The company also announced positive clinical data, reporting a 24.6% objective response rate in patients with metastatic non-small-cell lung cancer. Shares of IOVA closed at $8.7 on November 4, 2026, prior to the release of these financial results which highlighted operational efficiency and growing demand for its therapies.